Get to know our clinical trials

Trial of rozanolixizumab in subjects with persistent or chronic primary immune thrombocytopenia

THE PURPOSE OF THIS ADDITIONAL PHARMACOGENOMIC RESEARCH IS TO COLLECT DNA AND RNA SAMPLES FOR POTENTIAL RESEARCH THAT MAY HELP DETERMINE SUSCEPTIBILITY TO PRIMARY IMMUNE THROMBOCYTOPENIA (PIT) AND/OR RESPONSE TO TREATMENT WITH ROZANOLIXIZUMAB OR DRUGS OF THAT TYPE IN THE MAIN STUDY.

Status
In recruitment
headquarters
Multisede

Technical Summary

  • OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF ROZANOLIXIZUMAB IN SUBJECTS WITH PERSISTENT OR CHRONIC PRIMARY IMMUNE THROMBOCYTOPENIA
  • Code EudraCT: 2019-000883-40
  • Protocol number: TP0004
  • Promoter: UCB Biopharma SRL
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.